PMID: 69827Jul 30, 1977Paper

Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Identification of abnormal central dopamine control

Lancet
K O StumpeH Vetter

Abstract

Plasma-prolactin concentration was up to four times higher in male patients with essential hypertension than in normotensive controls. Oral administration of bromocriptine, a dopaminergic agonist, suppressed plasma-prolactin and lowered arterial pressure. It is proposed that in the hypertensive patients the raised prolactin levels reflect a defect in central dopamine control which is normalised by bromocriptine. The antihypertensive effect of bromocriptine suggests that the dopaminergic system is involved in blood-pressure regulation and that reduced central dopaminergic activity may be a factor in the maintenance of essential hypertension.

Citations

Jan 1, 1979·The Journal of Pharmacy and Pharmacology·J D FlackR H Poyser
Sep 1, 1979·British Journal of Clinical Pharmacology·M J LewisA H Henderson
Jan 1, 1987·Clinical and Experimental Hypertension. Part A, Theory and Practice·L I Goldberg, M B Murphy
Oct 1, 1987·Clinical and Experimental Pharmacology & Physiology·B K Tan, J S Hutchinson
Jan 1, 1987·Clinical and Experimental Hypertension. Part A, Theory and Practice·B J Clark
Jan 1, 1985·European Journal of Clinical Pharmacology·E JungmannK Schöffling
Jan 1, 1986·European Journal of Clinical Pharmacology·L SteardoM Maj
Oct 1, 1982·Naunyn-Schmiedeberg's Archives of Pharmacology·R A Hahn, B R MacDonald
Jan 1, 1980·Clinical and Experimental Hypertension : CHE·T OgiharaY Kumahara
May 20, 2009·Hypertension·George A GeorgiopoulosChristos Papamichael
May 11, 2010·Journal of Hypertension·Luxia ZhangJohn P Forman
Oct 7, 2010·Journal of Endocrinological Investigation·T F KrzeminskiB Kos-Kudła
Jan 15, 2015·American Journal of Physiology. Renal Physiology·Megan M GreenleeDouglas C Eaton
Nov 1, 1988·Journal of Endocrinological Investigation·G P BerniniA Salvetti
Jan 1, 1989·Clinical and Experimental Hypertension. Part A, Theory and Practice·V MusumeciG Folli
Jan 1, 1987·Clinical and Experimental Hypertension. Part A, Theory and Practice·M G MarlettiniC Orlandi
Aug 1, 1987·Australian and New Zealand Journal of Medicine·J A WhitworthP Kincaid-Smith
Jan 1, 1986·European Journal of Clinical Pharmacology·R J WaldenB N Prichard
Jan 1, 1984·Clinical and Experimental Hypertension. Part A, Theory and Practice·S Matsuda, N Aoki
Sep 1, 1982·Journal of Autonomic Pharmacology·M F Lokhandwala, R J Barrett
Apr 1, 1984·British Journal of Clinical Pharmacology·D ManneringF Kemp
Dec 1, 2010·Clinical Endocrinology·Paraskevi MediskouJohn G Yovos
Feb 19, 2011·American Journal of Hypertension·Kimon S StamatelopoulosMaria Alevizaki
Dec 24, 2011·Clinical Journal of the American Society of Nephrology : CJASN·Juan Jesús CarreroMahmut Ilker Yilmaz
Dec 1, 1979·The Journal of Pharmacy and Pharmacology·A Gibson, M Samini
Jul 1, 1978·British Journal of Pharmacology·M G BogaertJ L Willems
Dec 1, 1979·The Journal of Pharmacy and Pharmacology·A F Sved, J D Fernstrom
May 1, 1978·The Journal of Pharmacy and Pharmacology·A Gibson, M Samini
Jan 1, 1986·Acta Medica Scandinavica. Supplementum·I OsI Eide
Apr 1, 1990·Journal of Autonomic Pharmacology·J RoquebertA Morán Benito
Jan 1, 1990·Archives of Gynecology and Obstetrics·M G MarlettiniC Orlandi
Jul 1, 1980·British Journal of Obstetrics and Gynaecology·D M Jenkins, M H Soltan
Jan 1, 1983·Clinical and Experimental Hypertension. Part A, Theory and Practice·H KawabeT Saruta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.